Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we comprised some of the most interesting conversations from Mind Moments podcast episodes in 2023, highlighting research in neurology that moves the field forward. The NeurologyLive team included several reaction episodes to FDA approved medicines, providing clinicians an overview of what they can expect from these new therapies and how they will be used in clinic going forward. Those included in this week's episode, in order of appearance, are:

Sharon Cohen, MD, FRCPC, behavioral neurologist and medical director of the Toronto Memory Program at the University of Toronto, and a trial investigator for Clarity AD, the phase 3 trial of lecanemab. 

• Check out the full episode here: https://www.neurologylive.com/view/special-episode-lecanemab-approved-for-alzheimer-disease

Robert A. Hauser, MD, MBA, director of the Parkinson’s and Movement Disorders Center at the University of South Florida.

• Check out the full episode here: https://www.neurologylive.com/view/episode-81-widening-therapeutic-window-parkinson-disease

Alberto Espay, MD, PhD, the division director and Research Endowed Chair of the James J. and Joan A. Gardner Family Center for Parkinson’s Disease and Movement Disorders, and a professor of clinical neurology and rehabilitation medicine at the University of Cincinnati.

• Check out the full episode here: https://www.neurologylive.com/view/episode-94-discussion-leqembi-lecanemab-approval-alzheimer-disease

Carolina Ferreira Atuesta, MD, MSc, a scientific researcher and clinical data manager at the Icahn School of Medicine at Mount Sinai.

• Check out the full episode here: https://www.neurologylive.com/view/episode-82-managing-seizures-after-ischemic-stroke

Natalie Goedeker, CPNP, a nurse practitioner in neurology in the Neuromuscular Division at Washington University in St Louis.

• Check out the full episode here: https://www.neurologylive.com/view/special-episode-tofersen-approved-sod1-als

Episode Breakdown:

1:20 – Cohen on the safety of lecanemab, including the 3 patient deaths reported in the supportive clinical trial program. 

6:25 – Hauser on the clinical advantages of IPX203, a potential new carbidopa/levodopa formulation for patients with Parkinson disease. 

9:20 – Espay on tempering expectations of lecanemab and other antiamyloid therapies in the treatment of Alzheimer disease.

13:20 – Atuesta on the lack of standardized methods for monitoring patients with poststroke seizures, including elders.

17:00 – Goedeker on the approval of gene therapy SRP-9001 for patients with Duchenne muscular dystrophy, the integration process, and safety considerations clinicians should be aware of.

This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com.

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.